PDCD1 and melanoma: Clinical studies are ongoing to investigate relationships between anti-PD-1 antibody response and the plasma levels of CXCR2-dependent chemokines as well as genetic inflammasome polymorphisms in advanced melanoma patients undergoing checkpoint inhibitor therapy.